Clearside Biomedical, Inc. (NASDAQ:CLSD – Get Free Report) was the target of a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 767,400 shares, a growth of 34.3% from the February 13th total of 571,300 shares. Currently, 1.1% of the company’s shares are sold short. Based on an average daily trading volume, of 258,500 shares, the days-to-cover ratio is currently 3.0 days.
Wall Street Analysts Forecast Growth
A number of research firms have issued reports on CLSD. HC Wainwright reissued a “buy” rating and set a $6.00 price target on shares of Clearside Biomedical in a research report on Thursday, March 6th. Needham & Company LLC reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Clearside Biomedical in a research note on Thursday, March 6th. Finally, StockNews.com raised shares of Clearside Biomedical from a “sell” rating to a “hold” rating in a research report on Thursday, December 12th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $5.75.
Read Our Latest Analysis on Clearside Biomedical
Institutional Investors Weigh In On Clearside Biomedical
Clearside Biomedical Stock Down 3.3 %
CLSD opened at $0.86 on Monday. The firm’s 50 day moving average is $0.95 and its 200-day moving average is $1.05. Clearside Biomedical has a 52-week low of $0.77 and a 52-week high of $1.80. The firm has a market capitalization of $65.23 million, a P/E ratio of -1.91 and a beta of 2.10.
About Clearside Biomedical
Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.
See Also
- Five stocks we like better than Clearside Biomedical
- 3 Stocks to Consider Buying in October
- Consumers Are Cutting Back, But These 3 Stocks Will Stay Strong
- Profitably Trade Stocks at 52-Week Highs
- Disney Stock: 4 Key Metrics Validating Its Comeback
- How to Calculate Return on Investment (ROI)
- Resilient Investing: 3 Stocks Built to Weather Market Volatility
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.